Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 2.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,133 shares of the biotechnology company’s stock after selling 289 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Axon Enterprise were worth $3,864,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of AXON. Motley Fool Asset Management LLC boosted its holdings in Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after purchasing an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in Axon Enterprise in the first quarter valued at about $81,630,000. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Axon Enterprise by 110.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock valued at $71,302,000 after purchasing an additional 144,568 shares during the last quarter. Finally, Swedbank AB purchased a new position in Axon Enterprise in the first quarter valued at about $39,923,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the sale, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total value of $318,177.00. Following the sale, the director now directly owns 3,653 shares in the company, valued at approximately $1,291,445.09. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the sale, the director now owns 27,259 shares in the company, valued at $10,385,406.41. The disclosure for this sale can be found here. Insiders have sold a total of 317,981 shares of company stock worth $115,662,734 in the last three months. 6.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AXON shares. Needham & Company LLC reissued a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a report on Wednesday, August 7th. Bank of America started coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price on the stock. Craig Hallum increased their target price on Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Jefferies Financial Group started coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $385.00 target price on the stock. Finally, Robert W. Baird increased their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

Axon Enterprise Stock Up 0.9 %

Shares of Axon Enterprise stock opened at $393.29 on Monday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The business’s 50 day simple moving average is $348.04 and its 200-day simple moving average is $317.24. The stock has a market capitalization of $29.68 billion, a price-to-earnings ratio of 115.00, a PEG ratio of 10.34 and a beta of 0.94. Axon Enterprise, Inc. has a twelve month low of $189.12 and a twelve month high of $393.58.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the prior year, the firm earned $0.80 EPS. The business’s quarterly revenue was up 34.5% on a year-over-year basis. Equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.